prostacyclin (PGI2). On the one hand, in platelets arachidonic acid is mainly converted to thromboxane A2, an unstable (half life 30 seconds) vasoconstrictor and platelet aggregating substance. On the other, in the vessel wall arachidonic acid is converted to prostacyclin (PGI2), an unstable (half life two to three minutes) vasodilator and ants-aggregatng substance. We have proposed, therefore, that prostacyclin is the natural and main defence of the vessel wall against deposition of platelet aggregates. Further, prostacyclin and thromboxane A2 represent in biological terms the opposite poles of a homeostatic mechanism for the regulation of platelet aggregability in vivo. 4 Clearly, manipulation of this control mechanism is likely to affect thrombus and haemostatic plug formation.
Apart from platelets, some other tissues have also been shown to generate TXA2, including phagocytosing leucocytes. The role of TXA2 in tissues other than platelets is uncertain.
Prostacyclin is the main product of arachidonic acid in all arteries and veins so far tested. Not much is known about the microcirculation but microvessels, mainly capillaries, isolated from rat cerebrum generate predominantly prostacyclin. 5 The ability of the large vessel wall to synthesise prostacyclin is greatest at the intimal surface and progressively decreases towards the adventitia.6 Use of cultured cells from vessel walls additionally shows that endothelial cells are the most active producers of prostacyclin. Other cells, including myocytes in culture and mesenchymal cells (probably fibroblasts) also produce prostacyclin, as does the pericardium and the epicardial surface of the heart. Since the release of prostaglandins is increased by any distortion of cell membranes, it is interesting to speculate that with each beat of the heart the stretching of the parietal and visceral pericardia leads to a release of prostacyclin which may act as a natural lubricant between them. In this respect, the third activity of prostacycin (termed cytoprotection when applied to the reduction of experimentally induced ulcers in the stomach) could be important. The possibility also exists that any prostacyclin released will condition the surface coronary vessels and perhaps also be responsible for preventing the clotting of blood spilt into the pericardial sac.
Prostacyclin has been implicated in functional hyperaemia, the main evidence for which is in the gastric mucosa,7 where prostaglandin synthetase inhibitors such as aspirin and indomethacin reduce mucosal blood flow and cause erosions. The aspirinlike drugs, however, do not cause vasoconstriction in the normal coronary circulation either of animals or man, indicating that a continuous production of prostacyclin is not having a vasodilator activity in the normal heart. Interestingly, Friedman et al.8 found in nine patients with coronary artery disease (eight with angina) that indomethacin increased the blood pressure by an average of 20 mm, increased myocardial oxygen demand, and decreased coronary flow by 40%. The results are complicated by the fact that the patients were receiving beta-blockers and nitrates, each of which could be a source of interactions with indomethacin, but they do suggest that in coronary vascular disease the endogenous release of prostacyclin takes part in the struggle to maintain the coronary circulation.
There is also experimental evidence that exogenous prostacyclin has a beneficial effect in the acutely ischaemic heart. Infusions of prostacyclin intravenously have an antiarrhythmic effect in experimental infarction9 and also limit infarct size (in dogs and cats) and reduce lysosomal enzyme release. Several studies have now confirmed the original observations of Lefer et al. 10 including that of Ribeiro et al. 11 in which they showed a substantial decrease in infarct size and mor-six hours after ligating the left anterior descending coronary artery. Prostacyclin induced a reduced blood flow to the non-ischaemic myocardium and no change in the blood flow to the ischaemic myocardium, raising the possibility that this beneficial effect is connected with its "cytoprotective" activity rather than with its antiplatelet or vasodilator activity. In this context it is interesting that dogs are also protected against lethal endotoxin shock by prostacyclin infusions.12 This protection was associated with cardiac mitochondria which were structurally and functionally normal, in contrast to the depression and disruption produced by endotoxaemia, as observed by enzymic assay and electron microscopy. 13 The other side of the coin involves the role of platelets and thromboxane A2 release in coronary artery disease. In man, thromboxane release into the coronary sinus blood increases after angina, but it is difficult to know whether this is cause or effect, or which cells are responsible. Artefacts resulting from the use of long catheters have been suggested, but Hirsh et al. '4 have concluded that blood sampling across the heart through long catheters is a reliable procedure for the assessment of intracoronary thromboxane A2 production in patients with ischaemic heart disease. Certainly, if thromboxane A2 had a causative role in angina, aspirin should prevent its release and the consequent effects.
The discovery of prostacyclin and the possibility that a balance between prostacyclin and thromboxane formation regulates the haemostatic state of the circulation has led to intensive investigations of the role of prostacyclin in disease processes.
It has been suggested that a number of diseases are related to an imbalance in the prostacyclin-TXA2 system, including arterial and venous thrombosis, atherosclerosis, and diabetes. It is possible that in diseases where there is a tendency for thrombosis, TXA2 production is raised or prostacyclin production is reduced or both, while the opposite is found in some diseases associated with an increased bleeding ten Prostacyclin has been successfully used in a few cases of primary pulmonary hypertension41-43 and one case of pre-eclamptic toxaemia. 44 Yui et al.4s described beneficial effects of intravenous infusions of prostacyclin in nine patients with severe congestive heart failure refractory to digitalis and diuretics. Mean pulmonary capillary wedge pressure, mean arterial pressure, systemic and pulmonary vascular resistance were all reduced, whereas heart rate, cardiac index, and stroke index were increased. Facial flushing was the only side effect.
Bergman 57 and in hypoxic damage in the cat isolated perfused liver.58 Interestingly, the addition of prostacyclin during the separation from blood and the subsequent washing of platelets substantially improves their viability in vitro. Whereas normal platelet survival is about 10 hours, platelets prepared with the aid of prostacyclin remain functional for 72 hours.59 All of these studies suggest a potential wider therapeutic role of prostacyclin in cell or tissue preservation.
Clearly, our knowledge of the causes and treatment of cardiovascular diseases will be substantially increased in the next few years by studies on the formation of prostacyclin in the body and by therapeutic trials of prostacyclin and its analogues in various car diovascular diseases. 
